|
|
 |
|
Viewing report
|
|
|
|
The Cancer Biotherapy Research Group - Product Pipeline Review - Q4 2010
GlobalData, Dec 2010, Pages: 42
The Cancer Biotherapy Research Group – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “The Cancer Biotherapy Research Group – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by The Cancer Biotherapy Research Group.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The Cancer Biotherapy Research Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of The Cancer Biotherapy Research Group’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in The Cancer Biotherapy Research Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate The Cancer Biotherapy Research Group’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of The Cancer Biotherapy Research Group in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with The Cancer Biotherapy Research Group.
- Avoid Intellectual Property Rights related issues.
|
|
|
|
